ArticleBreast cancer (Dove Medical Press)2026
Efficacy and Safety of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Combined with Chemoimmunotherapy in Locally Advanced Breast Cancer: A Single-Center, Retrospective Pilot Study.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The combination of radiotherapy with immunotherapy holds synergistic potential, yet its role in the neoadjuvant treatment of breast cancer remains underexplored. This single-center, retrospective pilot study aimed to explore the preliminary efficacy and safety of integrating stereotactic body radiotherapy (SBRT) with chemoimmunotherapy as a novel neoadjuvant regimen for a small cohort of patients with high-risk, locally advanced breast cancer. Patients and Methods: Between June 2023 and August 2025, 20 patients received neoadjuvant SBRT (18Gy/3 fractions for node-positive; 24Gy/3 fractions for node-negative disease) concurrently with chemoimmunotherapy (various anti-PD-1/bispecific antibodies plus chemotherapy), followed by surgery. Key endpoints were pathological complete response (pCR, ypT0/Tis ypN0), near-pCR (Residual Cancer Burden [RCB] class 0 or I), objective response rate (ORR), and safety. Results: The cohort included triple-negative breast cancer (TNBC, 35%) and hormone receptor-positive/HER2-negative breast cancer of the Luminal B subtype (Luminal B/HER2-, 50%). Most had cT2 (75%) and node-positive (75%) disease. The median number of chemoimmunotherapy cycles were 8, with 80% receiving an AC-T backbone. The overall pCR rate was 45% (9/20). Efficacy varied by subtype: the pCR rate was 85.7% (6/7) in TNBC and 20% (2/10) in Luminal B/HER2- disease. Notably, 100% of TNBC and 40% of Luminal B/HER2- patients achieved near-pCR (RCB 0/I). ORR was 90%. Grade 3-4 adverse events occurred in 25% of patients, with no treatment-related mortality. Conclusion: In this single-center, retrospective pilot study, early integration of SBRT with chemoimmunotherapy demonstrated promising antitumor activity, particularly high pCR rates in TNBC and induction of deep pathological responses (RCB 0/I) in Luminal B/HER2- disease, with a manageable safety profile. Observed in a heterogeneous cohort, these preliminary findings highlight potential efficacy but require cautious interpretation and warrant validation in larger, prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.